Led by a team of industry experts and world-renowned academics, Synairgen is dedicated to creating pandemic-ready respiratory treatments we can all believe in.

An experienced Chief Financial Officer, Joseph is a Fellow Chartered Accountant with extensive listed company, finance, commercial and consulting experience. Most recently, he has held positions as executive and non-executive directors of listed early-stage life sciences companies, where Joseph led financial reporting, M&amp;A, strategy, and regulatory / corporate governance. Prior to this, Joseph spent ten years in senior leadership roles in the Kantar division of WPP PLC, including CFO at Kantar Futures, and Global Commercial Director of TNS, a multi-billion-dollar global market research agency. Joseph qualified as a chartered Accountant in the audit practice of Mazars LLP.

Joseph Colliver

Dr Marcin Mankowski was appointed Chief Medical Officer at Synairgen in October 2023. He is an experienced pharmaceutical physician and drug developer with 27 years of pharmaceutical industry experience. Marcin has been a consultant to Synairgen since 2018 in a part-time capacity, latterly as acting CMO. Between 2021 and 2023 he worked as Chief Executive Officer at tranScrip Ltd, which he co-founded in 2008. During his tenure at tranScrip he played an integral role in managing investment, leading a vast range of projects across all stages of drug and executing on the strategy of clinical development programs across different therapy areas, with particular focus on infectious diseases and respiratory medicine. Prior to this, he worked at Chiron Biopharmaceuticals and Bristol-Myers Squibb.

Dr Marcin Mankowski

Amanda Radford FCA is an independent non-executive director and Chair of the Audit Committee since December 2022. 
Amanda is an internationally experienced finance leader with substantial listed company expertise and is currently the Group Financial Controller of BSI Group, the global B2B company which employs around 5,500 people and generates revenues of c. £600M. Over the course of her career, Amanda has held senior finance roles in a number of public companies and has significant experience in external reporting, financial controls, forecasting and business planning as well as M&amp;A and fundraising. She has previously held senior positions at companies including Convatec Group plc, Post Office Ltd, Pets at Home Vet Group and TalkTalk Telecom Group. 
Starting her career as a qualified chartered accountant, Amanda trained at Deloitte prior to which she received a BSc in Biochemistry with Molecular &amp; Cell Biology from Birmingham University.

Amanda Radford FCA

Dr Flic Gabbay is an independent non-executive director and Chair of the Remuneration Committee of Synairgen, joining the Board in September 2022. Flic has extensive experience within the life sciences sector including holding several senior and CEO positions in big pharma, biotech and CROs in both Europe and North America. As Founder and Managing Partner at TranScrip LLP, founded in 2008, she has overseen drug development work with companies at all stages of the drug development cycle, as well as securing private equity investment and the acquisition of Real Regulatory.
Starting her career as a medical doctor, Flic held various medical posts across Europe before moving into the biotechnology sector. She is the current President of the Faculty of Pharmaceutical Medicine for the Royal Colleges of Physicians.
In 2020, Flic was awarded the Fellowship of the Academy of Medical Science and is passionate about bringing pharmaceutical medicine into mainstream medical science and its application to public health.
She completed a BSc in Pharmacology and a Bachelor of Medicine and Surgery degree at the University of Manchester.

Dr Flic Gabbay

Richard Marsden joined Synairgen in a consulting role as General Manager in November 2003, was appointed to the Board as Managing Director in June 2004 and was appointed Chief Executive Officer in September 2009. Between 1998 and 2003 he worked as Projects Manager and Cystic Fibrosis Business Development Manager at Profile Therapeutics plc, where he managed the Cystic Fibrosis business and played a major role in the development of its proprietary pharmaceutical unit, Profile Pharma Limited. Prior to this, he worked for Zimmer Limited, Genentech (UK) Limited and Roche Products Limited.

Richard Marsden

Stephen Holgate is a co-founder of Synairgen and was appointed a non-executive director in June 2003. After qualifying in Medicine at Charing Cross Hospital Medical School, London he has pursued an academic career leading to his appointment in 1987 to his current position as Medical Research Council Clinical Professor of Immunopharmacology at the University of Southampton. His research interests have been largely focused on the cellular and molecular mechanisms of asthma that has involved use of both epidemiological and genetic approaches. He has published over 1,300 papers in peer-reviewed literature.
He is Member of the Horizon 2020 Science Panel for Health; Board Chair of the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs); Chairman of Defra’s Hazardous Substances Advisory Committee; Trustee and Chair of the Research Strategy Committee of Cancer Research UK; Trustee and Chair of the Grants Panel of the Great Ormond Street Hospital Children's Charity; Trustee and Chair of The Kennedy Trust for Rheumatology Research; Member of the Governing Body of Nuffield Council for Bioethics; and Member of the Natural Environment research Council. He serves on a number of Advisory Committees in industry, including scientific board member or advisor to a number of companies involved in developing new treatments for airways diseases.

Professor Sir Stephen Holgate

Dr Bruce Campbell joined Synairgen as a non-executive director in April 2006. He has 50 years of drug development experience and has developed many drugs in a wide range of indications which are now on the market. He currently acts as a consultant to various companies including BenevolentAI and Syncona. Formerly he was Senior VP of International Development at Neurocrine Biosciences, Inc. (‘Neurocrine’). Prior to joining Neurocrine he worked for 27 years at Servier (United Kingdom), latterly as Scientific Director. In addition, he has also been a director and European Chairman of the Drug Information Association, a member of the European ICH Safety Working Party and a scientific advisor to IP Group plc.

Dr Bruce Campbell

Iain Buchanan was appointed as a non-executive director in June 2010 and brings to the company over 40 years of management experience in the pharmaceutical and biotech industries. Most recently he was CEO of NOXXON Pharma AG based in Berlin and previously he was CEO of Novexel S.A. based in Paris. 
He joined Novexel from Vertex Pharmaceuticals where he established the European affiliate. Prior to Vertex, Iain managed the international licensee business of Cilag AG – a subsidiary of Johnson and Johnson – based in Switzerland. Iain serves as a non-executive director for Allecra Therapeutics GmbH and Celloryx AG.

Iain Buchanan

Gareth Walters joined Synairgen in October 2021, and brings a wide range of experience from preclinical, to marketing authorisation, through to post-approval and commercialisation. Before joining Synairgen, Gareth served as Global Regulatory Affairs Head (Research &amp; Early Development) and Head of European Regulatory Affairs for Chugai Pharmaceuticals, where he led strategic and operational regulatory activities in Europe, Japan and the US. Prior to his time at Chugai, he held various senior regulatory and executive management and Board roles at several pharmaceutical and biotech companies, as well as commercial and clinical positions at Roche. During this time he played a key role in bringing innovative new medicines to the market, including in the US and Europe.

Dr Gareth Walters

Richard Francis joined in September 2021 as Head of CMC, bringing more than 35 years of experience in the development, manufacturing, regulatory approval and commercialization of many biopharmaceutical products including Cablivi®, Orthoclone OKT3®, Remicade®, and ReoPro®.

Richard Francis

Dr Phillip Monk joined Synairgen in October 2006 as Head of Bioscience Development and was appointed to the Board as Chief Scientific Officer in September 2009. Phillip was previously Director of the Respiratory and Inflammation Biology group at Cambridge Antibody Technology (‘CAT’) and was discovery/early development project manager for tralokinumab, an anti-IL-13 therapeutic antibody, now an approved treatment for moderate-to-severe atopic dermatitis.
Prior to joining CAT, he worked at Bayer AG within the respiratory disease therapeutic area, focusing on the development of novel therapies for asthma, COPD and cystic fibrosis.

Dr Phillip Monk

Jody Brookes joined Synairgen as a Clinical Research Nurse in 2004 and was appointed as Head of Clinical Operations in December 2011. Jody has led Synairgen’s clinical trial activity during this time. Prior to joining Synairgen, she worked as a Clinical Research Nurse specialising in Respiratory trials at the University of Southampton, working on both commercial and non-commercial trials.

Jody Brookes

Simon Shaw joined Synairgen as executive Chairman on its inception in June 2003 and became non-executive Chairman in October of that year. He is Group Chief Financial Officer of Savills plc.
He was Chief Financial Officer of Gyrus Group PLC from 2003 until its sale to Olympus Corporation in 2008, having previously been Chief Operating Officer of Profile Therapeutics plc between 1998 and 2003. Between 1991 and 1997 he was a corporate financier, latterly at Hambros Bank Limited. He is a chartered accountant.

Simon Shaw

Careers

We are always on the lookout for amazing talent to help us reach our goals.

Member	Audit Committee	Remuneration & Nomination Committee
Simon Shaw: Non-Executive Chairman	member	member
Richard Marsden: Chief Executive Officer, Executive Director
Joseph Colliver: Chief Financial Officer, Executive Director
Dr Bruce Campbell: Non-Executive Director	member	member
Professor Sir Stephen Holgate: Co-Founder and Non-Executive Director
Dr Flic Gabbay: Non-Executive Director and Chair of the Remuneration Committee		chairperson
Amanda Radford FCA: Non-Executive Director and Chair of Audit Committee	chairperson

Meet the Team

Senior Management

Board of Directors

Board committee membership

Looking for a new challenge?